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EhADH112 is an Entamoeba histolytica Bro1 domain-containing protein, structurally related tomammalian ALIX and yeast BRO1,
both involved in the Endosomal Sorting Complexes Required for Transport (ESCRT)-mediated multivesicular bodies (MVB)
biogenesis. Here, we investigated an alternative role for EhADH112 in the MVB protein traﬃcking pathway by overexpressing
166 amino acids of its N-terminal Bro1 domain in trophozoites. Trophozoites displayed diminished phagocytosis rates and
accumulated exogenous Bro1 at cytoplasmic vesicles which aggregated into aberrant complexes at late stages of phagocytosis,
probably preventing EhADH112 function. Additionally, the existence of a putative E. histolytica ESCRT-III subunit (EhVps32)
presumably interacting with EhADH112, led us to perform pull-down experiments with GST-EhVps32 and [35S]-labeled
EhADH112 or EhADH112 derivatives, confirming EhVps32 binding to EhADH112 through its Bro1 domain. Our overall
results define EhADH112 as a novel member of ESCRT-accessory proteins transiently present at cellular surface and endosomal
compartments, probably contributing to MVB formation during phagocytosis.
1. Introduction
Entamoeba histolytica, the causative agent of human amoe-
biasis provokes the second worldwide highest rates of mor-
bidity and mortality due to protozoa [1]. E. histolytica tro-
phozoites obtain host nutrients from a very active uptake and
eﬃcient engulfment of bacteria, red blood cells (RBC), and
cell debris [2], which makes them to be considered as pro-
fessional phagocytes. Since E. histolytica phagocytosis-defi-
cient mutants have a diminished virulence in vitro and in vivo
[3, 4], and nonvirulent E. histolytica strains exhibit reduced
rates of phagocytosis [5], this cellular event has been defined
as a key virulence factor.
EhCPADH, an E. histolytica protein complex formed by
the EhADH112 adhesin and the EhCP112 cysteine protease,
has been widely involved in adherence to, phagocytosis,
and destruction of target cells [6]. Bioinformatics analysis
revealed that EhADH112 is structurally related to mam-
malian ALIX [7], an evolutionarily conserved, ubiquitously
expressed and multifunction scaﬀold protein, originally
identified by its association with proapoptotic signaling part-
ners [8, 9]. Additional evidence has established that ALIX
modulates other cellular mechanisms, including receptor
downregulation [10, 11], endosomal protein sorting [12–
14], integrin-mediated cell adhesion and extracellular matrix
assembly [15], actin-based cytoskeleton remodeling [16, 17],
and membrane invagination and abscission in cytokinesis
and retroviral budding [18].
ALIX is an abundant cytoplasmic protein with a mul-
timodular architecture containing an N-terminal “banana”-
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shaped Bro1 domain [19], a middle “V”-shaped domain [20]
and a C-terminal proline-rich region [21]. This tripartite
domain organization occurs in the majority of ALIX ortho-
logues and provides them multiple protein-binding sites for
specific roles in several cellular processes, and the possibility
of linking proteins into distinct networks, thus acting as
scaﬀold proteins [22].
Much of what is known about ALIX has stemmed from
the characterization of its closest orthologue, yeast BRO1,
a crucial component of the Endosomal Sorting Complexes
Required for Transport (ESCRT) pathway [23, 24]. The
ESCRT machinery comprises a set of protein complexes
(ESCRT-0,-I, -II, -III, and -associated proteins) most of them
constituted by the so-called Vacuolar protein sorting (Vps)
factors. The assembly of the ESCRT apparatus at the endos-
omal surface is required to selectively transport ubiq-
uitinated receptors and other cargo proteins into late endo-
somes known as multivesicular bodies (MVB), towards final
degradation into the vacuole or lysosome [25, 26]. In this
process, human ALIX or yeast BRO1 promotes endosomal
membrane scission for intraluminal vesicles formation of
MVB, drived by the direct association of their N-terminal
Bro1 domains to the human CHMP4 or yeast Vps32 (also
named Snf7) ESCRT-III subunits, respectively [19, 20].
Despite significant advances in the understanding of
EhADH112 functions related to parasite virulence [6], its
structural relationship with ALIX and BRO1 proteins [7]
and recent evidence regarding the existence of most ESCRT
components [27] and MVB-like organelles in E. histolytica
[28], the potential role of EhADH112 in ESCRT-dependent
protein sorting and traﬃcking along the MVB pathway had
not yet been explored. The Bro1 domain occurs in a wide
group of eukaryotic proteins that serve as scaﬀold for link-
ing diﬀerent cellular networks, including MVB formation
dependent on ESCRT. In fact, a well-known hallmark for
Bro1 domain functionality is its ability to bind to ESCRT-
III subunits. Here, we initiated the characterization of the
N-terminal residues comprising the small EhADH112 Bro1
domain originally defined by the Pfam protein domain
database [29], but later extended by crystallographic experi-
ments [19]. The tertiary structure modeling of EhADH112,
presented in this study, predicted the spatial conformation
needed for putative interaction with ESCRT-III subunits via
the Bro1 domain. To explore if EhADH112 could be involved
in MVB formation during phagocytosis, we generated a
trophozoite population (ANeoBro1) overexpressing the first
166 amino acids of the EhADH112 Bro1 domain. ANeo-
Bro1 trophozoites dramatically diminished their rates of
phagocytosis, possibly due to an impairment of EhADH112
functions, seemingly produced by exogenous Bro1 accumu-
lation in cytoplasmic vesicles and aberrant complexes, and
its absence in plasma membrane and phagosomes, where
EhADH112 exerts its role for target cell adherence and
phagocytosis. Electron immunolocation of EhADH112 in
structures resembling MVB, together with its finding in
both soluble and insoluble subcellular fractions, suggested its
participation in MVB formation. Moreover, EhADH112 in
vitro binding to a protein homologous to Vps32 (EhVps32),
strengthened our hypothesis regarding the EhADH112
contribution to ESCRT-mediated protein sorting along the
MVB pathway by virtue of its Bro1 domain. Altogether,
our results define EhADH112 as a novel member of Bro1
domain-containing proteins present at cellular surface and
endosomal compartments with a potential role in the MVB
pathway.
2. Materials andMethods
2.1. Tertiary (3D) Protein Modeling. The EhADH112 pri-
mary sequence was submitted to the Phyre Server (http://
www.sbg.bio.ic.ac.uk/∼phyre/) and validated by the Swiss
Model Database. EhADH112 3D modeling was performed
with human ALIX (2oev) and yeast BRO1 (1z1b) crys-
tallized sequences as templates. Results were documented
and analyzed through the DeepView-Swiss-Pdb Viewer soft-
ware.
2.2. E. histolytica Cultures. Trophozoites of clone A (strain
HM1: IMSS) were axenically cultured in TYI-S-33 medium
at 37◦C [30]. Medium for transfected trophozoites (ANeo,
ANeoADH112 and ANeoBro1 populations) was supple-
mented with 40 μg/mL geneticin (G418) (Life Technologies,
Gaithesburg, MD). Trophozoites were harvested in logarith-
mic growth phase for all experiments and cell viability was
monitored by microscopy using Trypan blue dye exclusion
tests.
2.3. PCR Amplification of the Bro1-FLAG Encoding Fragment.
A 498 bp fragment from the 5′ end of the EhAdh112 gene,
corresponding to the first 166 amino acids of the
EhADH112-Bro1 domain was PCR-amplified, using the
sense (1–24 EhAdh112 nt) 5′-GGGGTACCATGAATAGAC-
AATTCATTCCTGAA-3′ and the antisense (477–497
EhAdh112 nt) 5′-CGGGATCCTTACTTATCGTCGTCATC
CTTGTAATCACTACCTGCTGCACATAGTTGG-3′ oligo-
nucleotides, 10mM dNTPs, 100 ng of E. histolytica genomic
DNA as template and 2.5U of TaqDNA polymerase (Gibco).
PCR was carried out for 30 cycles comprising 1min at 94◦C,
30 sec at 59◦C, and 40 sec at 72◦C. The sense oligonucleotide
contained a KpnI restriction site, whereas the antisense
oligonucleotide contained the FLAG (DYKDDDDK) tag-
encoding sequence (underlined) [31] and a BamH1 restric-
tion site. Oligonucleotides used in this work specifically
recognize sequences present in the EhAdh112 gene but not
those present in the previously reported EhAdh112-like genes
[7].
2.4. Generation of ANeoBro1 Trophozoites by Transfection with
the pNeoBro1FLAG Plasmid. The PCR-amplified product
(Bro1FLAG) was cloned into the BamH1 and KpnI sites of
the pExEhNeo (pNeo) plasmid, which contains E. histolytica-
specific transcription signals and the G418 resistance (NeoR)
conferring gene as selectable marker [32], producing the
pNeoBro1FLAG construct. Escherichia coli DH5α bacteria
were transformed with the pNeoBro1FLAG or pNeo plas-
mids. Both plasmids were purified using the QIAGEN Maxi
kit (Chatsworth, CA) and automatically sequenced. Plasmids
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(200 μg) were transfected by electroporation as previously
described [32] into exponentially growing trophozoites of
clone A, generating the ANeo and ANeoBro1 trophozoite
populations.
2.5. RT-PCR Experiments. cDNAs were synthesized using
1 μg of DNase-treated total RNA, 10mMdNTPs, 200 UAMV
reverse transcriptase (Gibco) and 0.5 μg of oligo dT (Gibco)
in a final volume of 10 μL, for 1 h at 42◦C. PCR amplifications
were carried out using 4 μL (∼330 ng) of cDNA, 1 U of
Taq polymerase, 2mM dNTPs, and 100 ng of the sense (1–
24 nt) and the antisense (477–497 nt) oligonucleotides from
the EhAdh112 gene. Additionally, the sense (1–17 nt) 5′-
ATGATTGAACAAGATGG-3′ and the antisense (780–794 nt)
5′-TTAGAAGAACTCGTC-3′ primers were used to amplify a
794 bp fragment of the NeoR gene. Each PCR was performed
as described above. Amplified products were separated by 1%
agarose gel electrophoresis, ethidium bromide-stained and
visualized in a Gel Doc 1000 apparatus (BioRad).
2.6. Immunofluorescence Assays. Trophozoites grown on
coverslips were fixed with 4% paraformaldehyde (PFA)
(Sigma) at 37◦C for 1 h, permeabilized with 0.5% Triton
X-100 in PBS (PBS-Triton) for 30min and incubated with
1% bovine serum albumin (BSA) for 40min at 37◦C.
Trophozoites were incubated with mouse monoclonal anti-
bodies against EhADH112 (mαEhADH112) (1 : 10) or rabbit
polyclonal anti-FLAG (pαFLAG) (USBiological) antibodies
(1 : 500), overnight (ON) at 4◦C, followed by incubation
with fluorescein-isothiocyanate (FITC)-labeled anti-mouse
or anti-rabbit secondary antibodies (1 : 100) (Zymed),
respectively, for 1 h at 37◦C.
For colocalization experiments, PFA-fixed trophozoites
were incubated ON at 4◦C with mαEhADH112 and pαFLAG
antibodies, followed (1 h at 37◦C) by FITC-labeled anti-
mouse IgM and tetramethyl-rhodamine-isothiocyanate-
(TRITC)-labeled anti-rabbit IgG secondary antibodies. For
some experiments, trophozoites were first incubated with
fresh RBC (1 : 40) for diﬀerent times at 37◦C, fixed with
PFA, contrasted with 3mM diaminobenzidine (DAB) and
treated for immunofluorescence assays as above. All prepa-
rations were preserved using the antifade reagent Vectashield
(Vector) and examined through aNikon invertedmicroscope
attached to a laser confocal scanning system (Leica).
2.7. Adherence and Phagocytosis Kinetics. Trophozoites were
incubated for 5, 10, and 15min with freshly obtained human
RBC (108 cells/mL) (1 : 100 ratio) at 4◦C for adherence, or
at 37◦C for phagocytosis experiments [33]. RBC were
contrasted with DAB and counted at random from three
independent experiments to determine the number of RBC
adhered to or ingested by 100 trophozoites.
2.8. Transmission Electron Microscopy (TEM) Assays. Fast-
freeze fixation followed by cryosubstitution was used for
ultrastructural location of EhADH112 and the FLAG-tagged
Bro1 recombinant polypeptide. Transfected trophozoites
were pelleted and placed into the hole of a 7mm diameter
antiadhesive plastic ring positioned on a foam rubber sup-
port and frozen on a copper mirror precooled to liquid
nitrogen temperature using a Reichert KF 80 unit. Freeze
substitution was achieved with a Reichert CS autosystem in
acetone containing 4% osmium tetroxide for 48 h at −80◦C.
Afterwards, samples were brought to room temperature at
a rate of 4◦C/h and embedded in epoxy resins. Ultrathin
sections were obtained and stained with uranyl acetate and
lead citrate. For immunogold labeling, thin sections were
placed on formvar-coated nickel grids and incubated for
15min in 0.1M ammonium chloride. Then, sections were
washed twice with PBS (5min each), blocked with 1%
BSA for 15min, and incubated with polyclonal rabbit anti-
EhADH112 (pαEhADH112) or monoclonal mouse anti-
FLAG (mαFLAG) (Sigma) antibodies at 1 : 50 or 1 : 20 dilu-
tions, respectively, for 60min. Then, sections were washed
and incubated for 1 h with goat anti-rabbit or anti-mouse
IgG (1 : 20) antibodies conjugated to 15 nm colloidal gold
(BBI International, Cardiﬀ, UK). Finally, sections were
washed and treated as above to be observed through a Zeiss
EM 910 electron microscope. For phagocytosis experiments,
trophozoites were first incubated with fresh RBC (1 : 40 ratio)
at 37◦C for 15min and treated for TEM as described.
2.9. Isolation of E. histolytica Membranes. E. histolytica cellu-
lar fractions were obtained as described by Aley et al. [34].
Briefly, trophozoites from wild-type clone A (40 × 106) were
harvested, washed twice with 19mM potassium phosphate
buﬀer, pH 7.2, and 0.27M NaCl (PD solution) and pooled.
Cell pellet was resuspended to 2 × 107 cells/mL PD solution
containing 10mM MgCl2 and rapidly mixed with an equal
volume of 1mg/mL concanavalin A in the same buﬀer. After
5min, cells were spun at 50×g for 1min to remove the
excess of concanavalin A. The supernatant was discarded
and cell pellet was resuspended in 12mL of 10mM Tris-
HCl buﬀer, pH 7.5, containing 2mM phenylmethylsulfonyl
fluoride (PMSF) and 1mM MgCl2. After 10min swelling in
hypotonic buﬀer, cells were homogenized by 18–20 strokes
of a glass Dounce homogenizer with a tight-fitting pestle
(Wheaton Scientific Div.). Cell lysis and membrane sheets
formation were verified by phase-contrast microscopy. The
homogenate was layered over a two-step gradient consisting
of 8mL of 0.5M mannitol over 4mL of 0.58M sucrose,
both in Tris buﬀer, and spun at 250×g for 30min. Material
remaining at the top of the 0.5M mannitol (SN1) was
centrifuged at 40 000×g for 1 h to separate soluble molecules
(SN2) from small membrane fragments and vesicles (P2).
Large plasma membrane fragments and other heavy debris
formed a tight pellet at the bottom of the gradient (P1). This
pellet was resuspended in 1mL Tris buﬀer containing 1M α-
methyl mannoside and left on ice for 40min with occasional
mixing. Plasma membranes free of concanavalin A were
diluted into three volumes of Tris buﬀer, homogenized by
80 strokes with a glass Dounce homogenizer, layered on a
20% sucrose Tris gradient and spun for 30min at 250×g.
Vesiculated plasma membranes floating above the initial
sucrose layer (SN3) were collected and then concentrated by
centrifugation at 40 000×g for 1 h. The pellet (P4), enriched
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in plasma membranes, was resuspended in Tris buﬀer. All
steps were performed at 4◦C. Samples (50 μg) were analyzed
by SDS-PAGE (10%) and transferred onto nitrocellulose
membranes for Western blot assays using rabbit polyclonal
antibodies against the last C-terminal 243 amino acids of
EhADH112 (pαEhADH243) and peroxidase-labeled anti-
rabbit IgG secondary antibodies, at 1 : 300 and 1 : 10 000
dilutions, respectively. As a control, mouse monoclonal anti-
E. histolytica actin and peroxidase-labeled anti-IgG cor-
responding secondary antibodies were used at 1 : 1 500 and
1 : 10 000, respectively.
2.10. In Vitro Binding Assays. A plasmid encoding glu-
tathione S-transferase (GST)-EhVps32 was constructed by
inserting a PCR fragment containing the EhVps32 coding
sequence into the BamH1 site of pGEX-5X-1 (Pharmacia).
Plasmids used for in vitro synthesis of EhAdh112 and
EhAdh112-truncated derivatives were constructed by insert-
ing PCR-amplified or restriction fragments containing
the corresponding EhADH112 coding sequences in the
polylinker of pGBKT7 (Clontech). GST-EhVps32 and GST
alone were expressed in E. coli BL21 bacteria. Cultures
(50mL) were induced at 30◦C after addition of 0.1mM
isopropyl-β-D-1-thiogalactopyranoside (IPTG) and incu-
bated for additional 2.5 h before proceeding with the GST
fusion protein purification [35]. [35S]-EhADH112 and [35S]-
EhADH112 truncated derivatives were synthesized in vitro
using the Promega TNT coupled transcription-translation
system in the presence of [35S] methionine (1 000Ci/mmol).
Labeling reaction (2 μl) was added to glutathione beads
loaded with GST-EhVps32 or GST proteins and incubated
at 4◦C for 1 h in 500mL of a 10mM Tris HCl, pH 8.0,
1mM EDTA and 150mM NaCl solution (STE) with 1%
(v/v) Triton X-100. After five washes with STE/1% Triton
X-100, beads were boiled in sample buﬀer and proteins
were separated by 10% polyacrylamide SDS-PAGE. Bound
proteins were detected by autoradiography or Coomassie
blue staining of gels.
3. Results and Discussion
3.1. Tertiary Structure Modeling of EhADH112 Predicts Con-
formational Similarities to ALIX. Bro1 domain-containing
proteins are highly conserved among eukaryotes and
exhibit distinct functions in several cellular processes
(Figure 1(a)), depending on the partners they interact with
[22]. EhADH112 displays 40% homology and 20% identity
to human ALIX [7] and its primary sequence aligns with
the portion of ALIX corresponding to the N-terminal Bro1
and the middle “V” domains. More divergent relatives of
ALIX only contain the Bro1 domain but otherwise, bear little
resemblance to the remaining structure [36, 37]. Although
EhADH112 lacks the proline-rich C-terminal tract that
harbors the majority of protein-binding sites linking ALIX
to various functions [7, 22], instead, this protein has a target
cell adherence domain, which binds to a 97 kDa protein in
epithelial cells [38]. Besides EhADH112, the E. histolytica
genome predicts two EhAdh112-related genes encoding the
EhADH112-like1 (898 amino acids) and EhADH112-like2
(919 amino acids) proteins [7], both displaying a putative
Bro1 domain at their N-terminus (Figure 1(a)). However, the
existence of these proteins has not yet been confirmed in
trophozoites.
Our current predictions for EhADH112 tertiary struc-
ture resulted in protein overlapping to ALIX (Figure 1(b)).
Models determined the boomerang or “banana”-shaped
spatial conformation for the N-terminal EhADH112 Bro1
domain, mostly made of α-helices forming a solenoid, with
helices 6 through 11 arranged in a tetratricopeptide repeat-
like structure [19], and a central core arranged in two
extended three-helix bundles forming elongated arms that
fold back into a “V” (Figure 1(b)). Arms conformation
suggests that the “V” domain may act as a hinge, changing
in response to ligand binding, as described for ESCRT
and viral proteins interaction with ALIX [18]. Apparently,
EhADH112 conserves the two hydrophobic patches [19]
required for ALIX or BRO1 endosomal membrane targeting
and association, via direct binding to ESCRT-III CHMP4 or
Vps32 subunits, respectively (Figures 1(b) and 1(c)), or Src-
tyrosine kinase docking. Since the conserved interaction of
ALIX or BRO1 with ESCRT-III is necessary for membrane
inward budding and MVB biogenesis during protein sorting
and traﬃcking [39], it is possible that EhADH112 could
associate to putative E. histolytica ESCRT-III components via
its Bro1 domain.
3.2. Generation of Trophozoites Overexpressing the Bro1
Recombinant Polypeptide. To initiate the characterization
of the EhADH112 Bro1 domain, trophozoites of clone A
(HM1:IMSS) were transfected with the pNeoBro1FLAG plas-
mid (Figure 1(d)) driving the expression of the recombinant
Bro1 polypeptide and generating the ANeoBro1 population.
The presence and expression of plasmids in trophozoites was
confirmed by RT-PCR amplification of the NeoR gene. NeoR
was amplified from ANeo (transfected with empty pNeo)
and ANeoBro1 trophozoites (Figure 1(e), lane 3), whereas
a transcript corresponding to the Bro1FLAG fragment, was
only detected in the ANeoBro1 population (Figure 1(e), lane
4), as expected. No amplification was detected in the absence
of reverse-transcriptase in reaction mixtures or using total
RNA from wild type clone A trophozoites (Figure 1(e), lanes
1 and 2).
3.3. ANeoBro1 Trophozoites Localize the Exogenous Bro1
Recombinant Polypeptide in Cytoplasmic Compartments. As
part of the EhCPADH complex, an E. histolytica surface
heterodimer involved in target cell adherence, phagocytosis,
and destruction, EhADH112 is located at trophozoite plasma
membrane and cytoplasmic vacuoles [6]. To determine the
location of the Bro1 polypeptide overexpressed by ANeoBro1
trophozoites and to distinguish it from the Bro1 domain
present in endogenous EhADH112, immunofluorescence
experiments were carried out using polyclonal antibodies
against the FLAG tag (pαFLAG) and monoclonal anti-
bodies (mαEhADH112) against the EhADH112 carboxy
terminus adherence epitope (444–601 amino acids). ANeo
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Figure 1: Structural features of EhADH112 and generation of ANeoBro1 trophozoites. (a) Structural features of representative Bro1 domain-
containing proteins and EhADH112- and EhADH112-like proteins: Bro1 domain (squares containing diagonal lines), coiled coil regions
(ellipses), proline-rich tracts (white squares), and adherence region (gray square). Hs: Homo sapiens; Sc: Saccharomyces cerevisiae; Eh:
Entamoeba histolytica. Numbers: amino acid number of each protein. (b-c) Spatial conformation of EhADH112 and its Bro1 domain. (b)
Ribbon representation for predicted EhADH112 tertiary and human ALIX crystallized structures and (c) Bro1 domains from EhADH112,
ALIX and yeast BRO1 proteins. N: amino terminus. C: carboxy terminus. TPR: tetratricopeptide repeat. (d) Schematic depiction of the
pNeoBro1FLAG plasmid. K:KpnI restriction site. B: BamH1 restriction site. (e) Transcripts obtained by RT-PCR assays using oligonucleotides
for theNeoR gene or Bro1FLAG sequence and cDNAs synthesized from nontransfected clones A (lane 2), ANeo (lane 3), and ANeoBro1 (lane
4). Lane 1 corresponds to the reaction mixture without reverse transcriptase, using total RNA from ANeoBro1.
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Figure 2: Cellular location of EhADH112 and the Bro1 recombinant polypeptide in transfected trophozoites. Confocal microscopy
images of permeabilized ANeo, ANeoBro1, or ANeoADH112 trophozoites incubated with (a) mαEhADH112 or (b) pαFLAG antibodies.
Negative controls correspond to trophozoite preparations only incubated with secondary antibodies. Top: phase contrast images. Bottom:
corresponding confocal sections. Arrowheads: small cytoplasmic vesicles.
trophozoites, as well as a trophozoite population named
ANeoADH112 that overexpresses the EhADH112 full length
protein fused to a FLAG tag (EhADH112-FLAG), were used
here as additional controls [7].
By confocal microscopy, mαEhADH112 antibodies re-
vealed the presence of EhADH112 at the plasma membrane
of permeabilized ANeo, ANeoBro1, and ANeoADH112 tro-
phozoites (Figure 2(a)), although fluorescence was higher in
ANeoADH112 population, since these trophozoites express
both, endogenous EhADH112 and exogenous EhADH112-
FLAG.
As expected, pαFLAG antibodies gave no reaction with
ANeo trophozoites (Figure 2(b)), but traced FLAG-tagged
Bro1 as punctuated structures and patches of diﬀerent sizes
in the cytoplasm of ANeoBro1 trophozoites. Interestingly, no
signals were detected at plasma membrane (Figure 2(b)),
suggesting that the EhADH112 carboxy end, absent in the
exogenous Bro1 recombinant polypeptide, could be partic-
ipating in EhADH112 targeting to the trophozoite surface.
Since EhADH112-FLAG appeared at the plasma membrane
(Figure 2(b)) and some cytoplasmic vacuoles (Figure 2(b),
arrowheads) of ANeoADH112 trophozoites, in a similar
pattern to the one exhibited by endogenous EhADH112 in
all parasite populations analyzed (Figure 2(a)), we rule out
that the FLAG tag could be causing the defective targeting
of recombinant Bro1 to the membrane. Negative results
were likewise obtained with nontransfected or transfected
trophozoites treated only with secondary antibodies. Here,
we show results obtained by assaying ANeo trophozoites
(Figures 2(a) and 2(b)).
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Figure 3: RBC adherence eﬃciency and rates of erythrophagocytosis exhibited by ANeo, ANeoBro1, and ANeoADH112 trophozoites. (a-b)
Trophozoites were incubated with RBC (1 : 100) at 4◦C for adherence and (c-d) at 37◦C for phagocytosis, for diﬀerent times. RBC were
contrasted with DAB and counted in 100 randomly selected trophozoites under the light microscope to obtain the mean of RBC adhered or
ingested by trophozoite. Bars represent the mean ± standard error of at least three independent experiments performed by duplicate.
From these experiments, we can conclude that the Bro1
recombinant polypeptide expressed by ANeoBro1 tropho-
zoites is located at a diﬀerent site than EhADH112, and that
transfection procedures or expression of FLAG-tagged pro-
teins did not aﬀect the location of endogenous EhADH112
in trophozoites.
3.4. Expression of the Exogenous Bro1 Recombinant Polypep-
tide by ANeoBro1 Trophozoites Diminishes Erythrophagocy-
tosis but Not Target Cell Adherence. EhADH112 has been
previously characterized by the properties conferred by its C-
terminus for target cell primary contact, internalization, and
phagocytosis [6, 38]. To further understand the Bro1 domain
contributions to EhADH112 functions in trophozoites, we
carried out RBC adherence and erythrophagocytosis assays.
Adherence eﬃciency and erythrophagocytosis rates exhibited
by ANeo trophozoites at 15min were taken as 100% in
all experiments. Again, as an additional control we used
ANeoADH112 trophozoites.
After 15min of RBC incubation at 4◦C, ANeo and ANe-
oBro1 trophozoites adhered a mean of 5.7 ± 3 and 6.6 ± 2
RBC per trophozoite, respectively (Figures 3(a) and 3(b)),
meanwhile at 10 and 5min they adhered 4.78 ± 1 and
4.56 ± 2, and 2.73 ± 2 and 2.8 ± 2 RBC per trophozoite,
respectively. In contrast, ANeoADH112 showed an increased
avidity to attach RBC, by adhering above twice more RBC
than ANeo and ANeoBro1 at 15, 10, and 5min (12.5 ±
2, 8.7 ± 2 and 7 ± 2 RBC per trophozoite, respectively)
(Figures 3(a) and 3(b)). These results indicate that exogenous
expression of the Bro1 recombinant polypeptide did not
aﬀect the adherence function of trophozoites and suggest
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that the EhADH112 N-terminus may not be promoting
target cell binding.
Interestingly, noteworthy diﬀerences were found in assays
determining phagocytosis activity of transfected tropho-
zoites. ANeo trophozoites ingested 14.3±2 RBC per parasite
at 15min, 11.6± 2 RBC at 10min and 9.4± 2 RBC at 5min
(Figure 3(c)), whereas ANeoBro1 trophozoites only ingested
7.1 ± 2, 5 ± 2 and 2.8 ± 2 RBC per trophozoite at 15, 10
and 5min, respectively (Figures 3(c) and 3(d)). As pre-
viously reported [7], ANeoADH112 trophozoites exhibited
augmented phagocytosis rates, by ingesting 76% more RBC
than ANeo trophozoites at 15min of erythrophagocytosis
(Figures 3(c) and 3(d)), and 40% and 10% more, at 10 and
5min, respectively (Figure 3(c)). These latter experiments
indicate that overexpression of Bro1 results in a dominant
negative eﬀect on phagocytosis. We hypothesized that this
phenomenon may be due to recruitment and association of
proteins probably involved in target cell internalization and
phagocytosis by the truncated EhADH112 protein instead
of the endogenous one, thus producing a competition
for protein binding sites and reducing trophozoites rates
of ingestion, despite eﬃcient primary cell contact. Oth-
erwise, the Bro1 recombinant polypeptide per se, could
be producing a conformational change in EhADH112 or
preventing EhADH112 accessibility for the interaction with
its counterparts, therefore causing a functional impairment.
Transfection procedures did not modify EhADH112
location and function, since ANeo trophozoites displayed
similar results to the ones presented by nontransfected clone
A trophozoites (data not shown).
3.5. The Bro1 Recombinant Polypeptide Exhibits a Diﬀerent
Cellular Location to Endogenous EhADH112 during Phago-
cytosis. Previous work using TEM and immunofluorescence
experiments determined that the EhADH112 C-terminus
mediates target cell adherence but also contributes to
phagocytosis activity of E. histolytica trophozoites [6, 38].
The diminished phagocytosis rates exhibited by ANeoBro1
trophozoites led us to precise the location of EhADH112
and the overexpressed Bro1 polypeptide after 5min of
erythrophagocytosis.
Through confocal microscopy, and in agreement to pre-
ceding findings, EhADH112 was detected at plasma mem-
brane, target cell contact sites, membrane extensions, and
phagosomes of nontransfected clone A trophozoites (data
not shown). A similar location was determined for
EhADH112 in ANeo trophozoites (data not shown), which
adhere to and phagocyte RBC in the same way than wild-
type trophozoites do. Regarding ANeoBro1 trophozoites
(Figure 4(a)), we observed EhADH112 at the trophozoite
plasma membrane, cytoplasmic vacuoles and phagosomes
(Figure 4(a), top). Besides, small phagosome-neighbouring
vesicles that may correspond to endosomes or lysosomes
were detected (Figure 4(a), asterisks). Otherwise, the Bro1
recombinant polypeptide was found in cytoplasmic punctu-
ated and vesicular structures and, significantly, it was accu-
mulated in vacuolar compartments (Figure 4(a), arrows)
that did not overlap to RBC location (Figure 4(a)). Images
also evidenced that exogenous Bro1 did not reach tropho-
zoites plasma membrane at early stages of phagocytosis
and was absent in RBC-containing phagosomes. The dif-
ferent location of EhADH112 and recombinant Bro1 in
trophozoites under basal culture conditions, even during
phagocytosis, together with the impairment of ANeoBro1
erythrophagocytosis rates and the presence of aggregates
containing exogenous Bro1, suggest that this polypeptide
could be interfering with the function of trophozoite proteins
present at the plasma membrane, probably participating in
membrane remodeling and RBC internalization into phago-
somes. Control experiments, omitting primary antibodies
gave no signals in trophozoites (Figure 4(a), bottom).
3.6. Exogenous Bro1 Accumulates in Aberrant Compartments
at Late Stages of Phagocytosis. It has been previously shown
that endogenous EhADH112 protein changes its location
within trophozoites during RBC phagocytosis. After target
cell contact, this adhesin is translocated from the trophozoite
plasma membrane to the phagocytic vacuoles. As the
ingestion process advances, EhADH112 is found in RBC and
after 30min, it comes back to the plasma membrane [6]. To
elucidate whether exogenous Bro1 localizes at some point
to the plasma membrane or to phagosomes and to better
understand its fate along the erythrophagocytosis process, we
followed this recombinant polypeptide in ANeoBro1 tropho-
zoites at diﬀerent times of RBC ingestion. Immediately
after RBC interaction (0min), exogenous Bro1 appeared in
randomly distributed cytoplasmic vesicles and patches of
distinct sizes and morphologies (Figure 4(b)). As RBC inges-
tion progressed (5min), the exogenous Bro1 recombinant
polypeptide accumulated in a ring-like structure surround-
ing RBC-containing compartments probably corresponding
to phagosomes or phagolysosomes (Figure 4(b)). This Bro1-
enriched large structure achieved a closer proximity to RBC
at 10min of phagocytosis, although no RBC overlapping
was observed (Figure 4(b)). At late phagocytosis stages (15
and 20min), the Bro1 recombinant polypeptide appeared
in huge tubular structures (Figure 4(b)). In yeast, deletion
or inactivation of several Vps factors, which assemble into
the ESCRT machinery during protein sorting and traﬃcking
through endosomal compartments, induces the formation
of enlarged vacuolated and tubulated organelles that fail
to mature into MVB [40, 41]. Hence, the large vacuoles
observed in ANeoBro1 trophozoites may correspond to
aberrant endosomal compartments where the exogenous
Bro1 polypeptide is stuck, aﬀecting the dynamics of RBC
internalization from the membrane to the phagosomes.
Work in progress in our laboratory, using specific biochem-
ical markers, will allow us to determine the identity of these
structures.
Since immunoelectron microscopy is a key technique to
place macromolecular functions within a cellular context, we
addressed the ultrastructural location of exogenous Bro1 in
ANeoBro1 trophozoites under basal culture conditions and
at 15min of erythrophagocytosis. For these experiments we
used mouse monoclonal antibodies against the FLAG tag
(mαFLAG), which resulted to be more sensitive for specific
Journal of Biomedicine and Biotechnology 9
Phase contrast Merging
N
eg
at
iv
e 
co
n
tr
ol
m
α
E
h
A
D
H
11
2/
pα
FL
A
G
R
R
R
R
6 μm
6 μm
∗
∗
(a)
pα
FL
A
G
M
er
gi
n
g
20151050
7 μm
7 μm
(b)
0.5μm
PM
RBC
V
0.2μm0.1μm
(c)
Figure 4: Diﬀerential location of endogenous EhADH112 and the Bro1 recombinant polypeptide in ANeoBro1 trophozoites during
phagocytosis. (a) Cellular immunolocation of endogenous EhADH112 and exogenous Bro1 in ANeoBro1 trophozoites after RBC ingestion.
Trophozoites were incubated with RBC for 5min and permeabilized. Top: after RBC contrasting with DAB, EhADH112 was detected
by mαEhADH112 antibodies and FITC-labeled anti-mouse secondary antibodies. The FLAG-tagged Bro1 recombinant polypeptide was
detected by pαFLAG antibodies and TRITC-labeled anti-rabbit secondary antibodies. Bottom: trophozoites incubated with FITC-labeled
anti-mouse IgM and TRITC-labeled anti-rabbit IgG secondary antibodies. Preparations were examined through laser confocal microscopy.
R: RBC. Arrows: recombinant Bro1 containing vacuoles. Asterisks: EhADH112 present in endosomal or lysosomal-like compartments.
(b) Immunolocation of exogenous Bro1 in ANeoBro1 trophozoites at diﬀerent times of erythrophagocytosis. Trophozoites were incubated
with fresh RBC and treated as described above. The Bro1 recombinant polypeptide was detected by pαFLAG and FITC-labeled anti-rabbit
secondary antibodies. Preparations were examined through a laser confocal microscope. Top: confocal sections. Bottom: merging of phase
contrast images and laser confocal corresponding sections. Arrows: vesicles and large vacuoles containing exogenous Bro1. (c) Ultrastructural
location of exogenous Bro1 in ANeoBro1 trophozoites after RBC ingestion. Ultrathin sections of ANeoBro1 trophozoites were processed for
immunogold labeling and TEM as described above. The Bro1 recombinant polypeptide was detected by mαFLAG antibodies and gold-
labeled secondary antibodies. Left: plasma membrane (PM). Middle: a huge vacuole. Right: vacuoles in the proximity of RBC after 15min
phagocytosis. V: vacuole. Arrowheads: Bro1 gold-labeled particles.
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recognition of the FLAG-tagged Bro1 recombinant polypep-
tide than the pαFLAG ones.
In agreement with the immunofluorescence results
showed here (Figures 2, 4(a) and 4(b)), mαFLAG antibodies
did not reveal any signal at the plasma membrane of ANeo-
Bro1 trophozoites in culture (data not shown), and neither at
15min of RBC ingestion (Figure 4(c), left panel). Numerous
gold particles associated to fibrillar material were observed
within huge vesicles (Figure 4(c), middle panel) that might
correspond to the large vacuoles detected in Figures 4(a)
and 4(b). Moreover, mαFLAG antibodies recognized some
vesicles close to RBC (Figure 4(c), right panel), confirming
that recombinant Bro1 remains in vacuolar compartments of
diﬀerent sizes, but not in RBC or phagosomes (Figure 4(c),
right panel). Taken together, our immunolocation results
revealed that under culture conditions, exogenous Bro1 is
profusely distributed in diﬀerent-sized cytoplasmic vesicles
of ANeoBro1 trophozoites. Similarly, at initial steps of target
cell contact, the Bro1 recombinant polypeptide remains in
the cytoplasm of ANeoBro1 trophozoites, which preserve
their ability to attach to target cells, but significantly
decreased their phagocytosis rates. Location of exogenous
Bro1 in small structures that gradually come together to
transform into exaggerated vacuolar compartments at late
stages of phagocytosis suggests that at these sites, recom-
binant Bro1 could also be retaining proteins involved in
RBC internalization, targeting, and phagocytosis, some of
them even aﬀecting the function of EhADH112, or that this
huge protein complexes may block the recycling of proteins
back to the trophozoite membrane, where tentatively they
would contribute to the membrane remodeling and protein
assembly processes required for phagosome formation.
3.7. EhADH112 Localizes in Structures Resembling MVB in
ANeoBro1 Trophozoites. According to our immunofluores-
cence assays, the location of endogenous EhADH112 at
the plasma membrane of ANeoBro1 trophozoites was not
aﬀected by the overexpression of recombinant Bro1 under
basal conditions. In fact, this resulted in RBC adherence
eﬃciencies similar to that displayed by wild-type and ANeo
trophozoites. Since EhADH112 was also found in cytoplas-
mic vacuoles that could diﬀer or not from that in which
recombinant Bro1 accumulated, we assessed the ultrastruc-
tural location of EhADH112 in ANeoBro1 trophozoites by
immunogold labeling experiments, using polyclonal rabbit
antibodies against EhADH112 (pαEhADH112) (Figure 5),
which gave a better reactivity on frozen ultrathin sections
than mαEhADH112 ones. Of note, pαEhADH112 antibodies
do not recognize the EhADH112-like protein sequences
previously reported by our group, since Western blot assays
specifically detect the band corresponding to the predicted
molecular weight of EhADH112 (data not shown).
Through TEM, pαEhADH112 antibodies revealed
EhADH112 at the plasma membrane of both, ANeo (data
not shown) and ANeoBro1 trophozoites (Figure 5(b)). Gold
labeling was also observed at external and internal faces of
vesicle membranes and inside vesicles, frequently associated
to fibrillar and membranous material (Figures 5(c)–5(e)).
Interestingly, EhADH112 was abundant within large
vacuoles containing several tubular and vesicular structures.
Huge organelles, containing intraluminal vesicles of diﬀerent
sizes and shapes, the majority of them immunolabeled,
appeared in many trophozoites (Figure 5(c)). By their
morphology, these compartments may correspond to MVB,
which showed a high similarity to the ones described in
mammals by Denzer et al. [42]. We also detected numerous
whitish EhADH112-carrying vesicles outside electrodense
structures with lysosome appearance, which also exhibited
EhADH112 signals (Figure 5(d)). These lysosome-like
structures presented a delimiting double membrane labeled
with EhADH112 (Figures 5(d) and 5(e)). Strikingly, several
vacuolar structures, one contained inside the other, which
suppose membrane inward budding of vesicles (Figure 5(e),
arrows), bordered lysosome-like organelles and carried
EhADH112. Recurrent and profuse docking of EhADH112
to the membrane of diﬀerent-sized vesicles, suggest its
possible participation in protein sorting along endosomal
compartments and vesicle fusion processes (Figures 5(d)
and 5(e)).
3.8. EhADH112 Appeared on RBC and Phagosomes dur-
ing Phagocytosis. At the beginning of erythrophagocytosis,
trophozoite membrane proteins make contact with RBC.
Immediately, not yet well-understood signaling processes
occur, allowing the recruitment of molecules with diﬀerent
roles in the uptake and digestion of target cells. In this
paper, our immunofluorescence experiments evidenced that
overexpression of the Bro1 recombinant polypeptide in
ANeoBro1 trophozoites did not aﬀect EhADH112 location at
target cell contact sites and phagosomes (Figure 4(a)). Fur-
ther, TEM ultrastructural observations, located EhADH112
near to and at invaginating membranes surrounding RBC
in trophozoites of ANeo (data not shown) and ANeoBro1
populations (Figure 4(c)). Inside trophozoites, in the vicinity
of delimiting membranes surrounding RBC, several small
whitish vesicles were seen (Figure 6(b)), sometimes as if they
were being released from huge vesicles. By their appearance
[42], these vesicles may correspond to MVB (Figure 6(b),
asterisks). As phagocytosis advanced, more abundant gold
particles were found on RBC (Figures 6(b) and 6(c)). Fur-
thermore, around phagosomes containing RBC, we observed
whitish vesicles in arrangements apparently organized, some
of them labeled with gold particles (Figure 6(c)).
Mammalian ALIX and yeast BRO1 are cytoplasmic pro-
teins that associate with endosomal compartments to func-
tion in concert with components of the ESCRT machinery
during MVB formation [41, 43]. In the endocytic pathway,
MVB are formed from early endosomes and then, they fuse
to late endosomes or lysosomes [12, 44]. Here, our findings
strengthen the role of EhADH112 not only as an adhesin
at the trophozoite surface, but also as a protein whose
similarity to other Bro1 domain-containing proteins such as
ALIX, could assign it an alternative function in endosome,
phagosome, and MVB formation. The presence of gold
labeling at the surface of small vesicles at the proximity
of larger vacuoles could mean that EhADH112 is being
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Figure 5: Ultrastructural location of EhADH112 in ANeoBro1 trophozoites. Ultrathin sections of ANeo or ANeoBro1 trophozoites were first
prepared by cryosubstitution and incubated with pαEhADH112 and gold-labeled secondary antibodies, and then contrasted and analyzed
by TEM. (a) ANeoBro1 trophozoites only incubated with gold-labeled secondary antibodies. (b–e) EhADH112-immunogold labeling in (b)
plasma membrane (PM), (c) a structure resembling a MVB, (d) a lysosome-like organelle, (e) MVB and vesicles fusing to a lysosome. V:
vacuole. MVB: multivesicular bodies. Arrows: vesicular fusion areas. Arrowheads: EhADH112 gold-labeled molecules.
targeted to these sites to perform a putative function in
vesicle formation or that it is per se a conveyor protein
which carries other molecules involved in this process.
Moreover, the possibility of EhADH112 participation in
vesicle biogenesis implies that it could be translocated from
the plasma membrane to the delimiting membranes of
internal vesicles. Hence, EhADH112 could be a soluble or
insoluble membrane-associated protein, depending on its
function and the protein or proteins it binds to.
3.9. EhADH112 Is Mostly Present in Membrane Subcellular
Fractions. To investigate whether native EhADH112 remains
as a soluble or insoluble membrane-associated protein
in wild-type trophozoites, we carried out the procedure
described by Aley et al. [34] followed by Western blot
assays, using rabbit polyclonal antibodies against the last
243 amino acids of EhADH112 (pαEhADH243), which
detect the carboxy-terminus of the adhesin. pαEhDH243
antibodies recognized the expected 78 kDa band correspond-
ing to the EhADH112 molecular weight in crude extracts
(TP) obtained after disruption of trophozoites incubated
with concanavalin A in the presence of protease inhibitors
(Figure 7(a), left panel, lane 1). After centrifugation at 250
×g for 30min on a mannitol/sucrose gradient, EhADH112
appeared in the supernatant (SN1), which contains vesi-
cles, small membrane fragments, and soluble proteins
(Figure 7(a), left panel, lane 2). We also detected a weak band
in the pellet (P1), which contains large fragments of plasma
membranes and cell debris (Figure 7(a), left panel, lane 3).
As a control, we used mouse monoclonal antibodies against
actin (mαactin), which reacted with the corresponding
43 kDa protein in all fractions (Figure 7(a), left panel, lanes 1
to 3).
Then, we ultracentrifuged (40 000×g) the SN1 fraction
to obtain the supernatant (SN2), where soluble components
remain, and the pellet (P2), containing internal vesicles and
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Figure 6: Ultrastructural location of EhADH112 in ANeoBro1 trophozoites after RBC ingestion. After 15min of interaction with RBC,
ANeoBro1 trophozoites were processed for immunogold labeling using pαEhADH112 and secondary antibodies, and contrasted and
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cytoplasmic MVB. (b) MVB and RBC neighboring vesicles; (c) RBC surrounded by small vesicles. MVB: multivesicular bodies. RBC: red
blood cells. Arrowheads: EhADH112 gold-labeled molecules. Asterisk: disruption of a larger vacuole and release of vesicles.
small membrane fragments. EhADH112 was only found in
P2 (Figure 7(a), middle panel, lane 2), suggesting that it
could be mostly a membrane-associated protein. Actin was
also absent in the SN2 fraction and strongly detected in P2
(Figure 7(a), middle panel, lane 2).
Next, we processed the P1 fraction, that according to Aley
et al. [34], contains vesiculated and nonvesiculated plasma
membrane fragments. The P1 fraction (Figure 7(a), left
panel, lane 3) was homogenized with α-methyl mannoside
and centrifuged at 250×g on a sucrose cushion to sepa-
rate vesiculated (P4) from nonvesiculated membranes and
debris (P3). P3 did not react with pαEhADH243 antibodies
(Figure 7(a), right panel, lane 1), indicating that EhADH112
is poorly present in nonvesiculated membranes. Then, we
concentrated the supernatant (SN3) by ultracentrifugation
at 40 000×g to obtain vesiculated membrane fragments
(P4). pαEhADH243 antibodies revealed the presence of
EhADH112 in P4 (Figure 7(a), right panel, lane 2), thus,
confirming that this protein is associated to vesiculated
plasmamembrane fragments.Meanwhile, actin was localized
in P3 and P4, attached to nonvesiculated and vesiculated
plasma membranes (Figure 7(a), right panel, lanes 1 and 2).
These data showed the presence of EhADH112 in mem-
brane vesicles, supporting results obtained by microscopy
experiments. They also evidence that EhADH112 could be
associated to plasma membrane during the active vesicular
traﬃc exhibited by trophozoites, probably inside small
vesicles that eventually fuse to plasma membrane.
Most Bro1 domain-containing proteins are cytosolic, and
it has been noticed that ALIX is transiently recruited to
the plasma membrane to promote membrane fission during
budding and release of viral particles, in association to
late-acting ESCRT proteins [45]. EhADH112 was originally
described as a component of the heterodimeric EhCPADH
complex, present at trophozoite plasma membrane and
cytoplasmic vacuoles under culture conditions. Interest-
ingly, during erythrophagocytosis, this complex is found
at diﬀerent locations. First, the protein is found at the
trophozoite plasma membrane, particularly, at target cell
contact sites. Then, this protein is detected together to inter-
nalized erythrocytes, in phagosomes and phagolysosomes.
At late stages, the EhCPADH complex is detected again at
the trophozoite plasma membrane, thus suggesting protein
recycling or even, a putative participation of EhADH112 in
membrane remodeling. Additional evidence has consistently
confirmed the presence of EhADH112 in both, trophozoite
plasma membrane and cytoplasmic vesicles. According to
our current subcellular fractioning experiments, EhADH112
is mostly present in membrane fractions. However, as it was
shown in Figure 7(a), EhADH112 is also found in fractions
containing soluble proteins. Therefore, we cannot discard
the possibility that EhADH112 exists in soluble form under
particular conditions not yet explored. Since the precise
protein location is largely determined by its function in the
cell, it must be considered that Bro1 domain containing
proteins such as ALIX are ubiquitous in order to serve
as scaﬀold proteins connecting several biological processes.
Therefore, additional functions should be investigated for
EhADH112 to better understand its subcellular location in
trophozoites. Particularly, the presence of EhADH112 in
diﬀerent membrane compartments, strongly supports the
hypothesis that EhADH112 could perform a role in the
endocytic pathway, although it remains to be established if
the previously reported E. histolytica ESCRT machinery is
indeed participating in this process.
3.10. EhVps32 Binds to the N-Terminus of EhADH112. One
conserved feature of themajority of Bro1 domain-containing
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Figure 7: EhADH112 major presence in membrane subcellular fractions and EhADH112 interaction with EhVps32. (a) Location of
EhADH112 in wild-type trophozoites subcellular fractions. Proteins (50 μg) from diﬀerent fractions of trophozoite extracts were separated
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[35S]-EhADH112 derivatives. Left: purified GST and GST-EhVps32 fusion proteins or [35S]-EhADH112 and [35S]-truncated derivatives
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proteins is their ability to bind the ESCRT-III component
Vps32 or CHMP4. This interaction allows BRO1 or ALIX
targeting to endosomes during MVB formation and virus
budding [13, 19]. Here, we investigated whether EhADH112
interacts with an E. histolytica protein homologous to yeast
Vps32. First, we found in the E. histolytica genome database
a protein sequence (EhVps32) with an e-value of 2.5 e-
12, displaying 48% homology and 25% identity to yeast
Vps32. According to multiple sequence analysis and Pfam
database predictions, EhVps32 contains a Snf7 domain,
present in all members of the Snf7 family. Additionally,
the predicted EhVps32 secondary structure using the Jpred
program, suggested that EhVps32 conserves the charac-
teristic five α-helices present in the Snf7 family protein.
To confirm the predicted interaction between EhADH112
and EhVps32 proteins, pull down experiments were per-
formed. Thus, we expressed a GST-EhVps32 fusion protein
in bacteria. GST alone or purified GST-EhVps32 were
immobilized on glutathione-sepharose beads (Figure 7(b),
left panel, lanes 1 and 2, resp.) and incubated with [35S]-
labeled EhADH112 (Figure 7(b), left panel, lane 3) or [35S]-
EhADH112 (1-421 amino acids) (Figure 7(b), left panel, lane
4) and [35S]-EhADH112 (422–687 amino acids) derivatives
(Figure 7(b), left panel, lane 5), previously synthesized by
a coupled transcription-translation system, as described
in Section 2.10. GST-EhVps32 beads retained EhADH112
(Figure 7(b), right panel, lane 1), and the EhADH112
(1–421) derivative (Figure 7(b), right panel, lane 2), but
not the EhADH112 (422–687 amino acids) polypeptide
(Figure 7(b), right panel, lane 3). As expected, GST alone
was unable to bind EhADH112 and EhADH112 derivatives
(Figure 7(b), right panel, lanes 4 to 6). Proteins present in
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pull-down reaction mixtures were Coomassie blue stained
as an additional control (data not shown). Together, these
results strongly suggest that EhADH112 binds EhVps32
through the Bro1 domain, as it has been reported for other
Bro1 domain-containing proteins [19, 20].
Although we do not know yet the identity of other
proteins associated to or transported by EhADH112 in live
trophozoites, based on these results, we hypothesized that
EhADH112 may interact with ESCRT proteins in vivo, as
it has been reported for ALIX and BRO1 [19, 39, 46, 47].
Interestingly, EhADH112 seems to be a novel member of
a subfamily of Bro1 domain-containing proteins present at
cellular surface [48] that alternatively could regulate the
assembly of proteins at endosomal membranes for MVB
biogenesis. Translocation of EhADH112 from the plasma
membrane to internal vesicles, endosomes, or phagosomes
and back to the surface, could also be related to a scaﬀold
function, as it has been described for its homologues in
yeast and mammals [22]. However, protein partnerships in
diﬀerent cellular networks should be addressed further.
4. Conclusions
In this work, we reported for the first time the functional
characterization of the N-terminus of EhADH112, an E.
histolytica Bro1 domain-containing protein involved in par-
asite virulence. A dramatic decrease of phagocytosis rates
displayed by trophozoites overexpressing an EhADH112
Bro1 recombinant polypeptide, together with an exaggerated
accumulation of this protein in aberrant compartments,
suggested that the Bro1 domain recruits proteins participat-
ing in phagocytosis. Moreover, EhADH112 localization at
trophozoite plasma membrane, MVB and phagosomes and
in both soluble and insoluble subcellular fractions, provided
additional support for an alternative role for this protein in
the endosomal MVB pathway. This function is conserved
among Bro1 domain-containing proteins, which interact
with ESCRT components to associate to endosomes. Here,
we also showed the in vitro association of EhADH112 with
an E. histolytica protein homologous to the ESCRT-III Vps32
subunit, as a putative hallmark for EhADH112 Bro1 domain
function in endosomal protein sorting. Additional eﬀorts
should be made to better understand the role of EhADH112
in ESCRT-mediated MVB biogenesis and other functions
also assigned to Bro1 domain-containing proteins.
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